secwatch.observer — SEC 8-K summary
======================================

Issuer:     CEL SCI CORP (CVM)
CIK:        0000725363
Form:       8-K
Filed at:   2024-07-26T23:59:59+00:00
Accession:  0001654954-24-009490
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CEL-SCI bias analysis confirms Multikine survival benefit; 5-year survival 73% vs 45% in target population
--------------------------------------------------------------------------------

- Bias analysis found no confounding baseline parameters; treatment and control arms are balanced, no bias detected.
- Target population (no lymph node, low PD-L1): Multikine 5-year survival 73% vs 45% control; hazard ratio 0.35.
- Company plans 212-patient confirmatory registration study with FDA agreement.
- Entire Phase 3 study of 923 patients also showed no bias; CEO notes high confidence in repeating survival benefit.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/725363/000165495424009490/0001654954-24-009490-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/725363/000165495424009490/cvm_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-24-009490

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer